Go Deep
Alamar Biosciences, Inc.
Alamar Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,128 | -19.6 | 5.22 | 0.16 | 2,239.90 |
| Oct 2026 | 18,688 | -21.1 | 5.63 | 0.16 | 2,408.82 |
| Oct 2026 | 18,202 | -21.1 | 6.08 | 0.16 | 2,603.83 |
| Oct 2026 | 18,709 | -21.1 | 5.61 | 0.16 | 2,394.39 |
| Oct 2026 | 18,467 | -21.9 | 5.83 | 0.16 | 2,493.67 |
| Oct 2026 | 18,024 | -23.5 | 6.25 | 0.16 | 2,670.03 |
| Oct 2026 | 17,241 | -26.2 | 6.98 | 0.16 | 2,974.61 |
| Oct 2026 | 17,653 | -24.8 | 6.59 | 0.16 | 2,805.30 |
Alamar Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 29,427,000.0 | 26,035,000.0 | 16,162,000.0 | 13,091,000.0 |
| Net Profit | -13,199,000.0 | -21,325,000.0 | -7,023,000.0 | -7,659,000.0 |
| EPS | -0.2 | -0.3 | -0.1 | -0.1 |
Alamar Biosciences, Inc. Revenue & Profit: Last 2 Years
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Revenue | 74,211,000.0 | 25,142,000.0 |
| Net Profit | -29,819,000.0 | -47,073,000.0 |
| EPS | -0.4 | -0.7 |
Alamar Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Total Assets | 139,992,000.0 | 149,511,000.0 |
| Total Liabilities | 298,946,000.0 | 282,922,000.0 |
| Total Equity | -158,954,000.0 | -133,411,000.0 |
Owes vs Owns
Alamar Biosciences, Inc. owed $0.20 for every $1 it owned in Jun 2026, down from $1.89 in Dec 2024.
| Period | Jun 2026 | Dec 2025 | Dec 2024 |
|---|---|---|---|
| Owes vs Owns | 0.20× | 2.14× | 1.89× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Alamar Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 21.4%Receivables 9.1%Inventory 27.5%Fixed assets (tangible) 26.2%Intangible assets 1.4%Other assets 14.4%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 3.3%Payables 2.0%Other liabilities 94.1%
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Assets | ||
| Cash & short-term investments | 30.0 | 79.4 |
| Receivables | 12.8 | 7.3 |
| Inventory | 38.5 | 14.4 |
| Fixed assets (tangible) | 36.6 | 35.1 |
| Intangible assets | 2.0 | 2.0 |
| Long-term investments | 0.0 | 0.0 |
| Other assets | 20.1 | 11.3 |
| Liabilities & equity | ||
| Short-term debt | 2.1 | 1.9 |
| Long-term debt | 9.8 | 31.2 |
| Payables | 5.9 | 6.2 |
| Other liabilities | 281.2 | 243.6 |
| Shareholders' equity | -159.0 | -133.4 |
| Net tangible assets | -160.9 | -135.5 |
Alamar Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Operating Activities | -53,608,000.0 | -55,214,000.0 |
| Investing Activities | 46,176,000.0 | -53,933,000.0 |
| Financing Activities | 10,836,000.0 | 113,417,000.0 |